BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37399083)

  • 1. Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI.
    Savaridas SL; Vinnicombe SJ; Warwick V; Evans A
    Br J Radiol; 2023 Aug; 96(1148):20220921. PubMed ID: 37399083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
    Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P
    Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
    Patel BK; Hilal T; Covington M; Zhang N; Kosiorek HE; Lobbes M; Northfelt DW; Pockaj BA
    Ann Surg Oncol; 2018 May; 25(5):1350-1356. PubMed ID: 29516362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of Contrast-Enhanced Spectral Mammography and Digital Breast Tomosynthesis for Diagnosing and Treating Breast Cancer.
    Yang D; Gong F
    Med Sci Monit; 2023 Dec; 29():e941880. PubMed ID: 38087777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM.
    Bellini C; Bicchierai G; Amato F; Savi E; De Benedetto D; Di Naro F; Boeri C; Vanzi E; Miele V; Nori J
    Br J Radiol; 2022 Jun; 95(1134):20210927. PubMed ID: 35451312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Tang S; Xiang C; Yang Q
    Br J Radiol; 2020 Aug; 93(1112):20200301. PubMed ID: 32574075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy.
    Park J; Chae EY; Cha JH; Shin HJ; Choi WJ; Choi YW; Kim HH
    Eur J Radiol; 2018 Nov; 108():261-268. PubMed ID: 30396666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Value of Contrast-Enhanced Spectral Mammography in Comparison to Magnetic Resonance Imaging in Breast Lesions.
    Xing D; Lv Y; Sun B; Xie H; Dong J; Hao C; Chen Q; Chi X
    J Comput Assist Tomogr; 2019; 43(2):245-251. PubMed ID: 30531546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation.
    Fallenberg EM; Schmitzberger FF; Amer H; Ingold-Heppner B; Balleyguier C; Diekmann F; Engelken F; Mann RM; Renz DM; Bick U; Hamm B; Dromain C
    Eur Radiol; 2017 Jul; 27(7):2752-2764. PubMed ID: 27896471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
    AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between breast MRI and contrast-enhanced spectral mammography.
    Łuczyńska E; Heinze-Paluchowska S; Hendrick E; Dyczek S; Ryś J; Herman K; Blecharz P; Jakubowicz J
    Med Sci Monit; 2015 May; 21():1358-67. PubMed ID: 25963880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Enhancement Intensity in Contrast Enhancement Spectral Mammography and Types of Kinetic Curves in Magnetic Resonance Imaging.
    Rudnicki W; Heinze S; Piegza T; Pawlak M; Kojs Z; Łuczyńska E
    Med Sci Monit; 2020 Mar; 26():e920742. PubMed ID: 32173716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): A retrospective comparison in 66 breast lesions.
    Li L; Roth R; Germaine P; Ren S; Lee M; Hunter K; Tinney E; Liao L
    Diagn Interv Imaging; 2017 Feb; 98(2):113-123. PubMed ID: 27687829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced spectral mammography in patients with MRI contraindications.
    Richter V; Hatterman V; Preibsch H; Bahrs SD; Hahn M; Nikolaou K; Wiesinger B
    Acta Radiol; 2018 Jul; 59(7):798-805. PubMed ID: 29058963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of background parenchymal enhancement (BPE) on contrast enhanced spectral mammography compared with magnetic resonance imaging.
    Luczynska E; Pawlak M; Piegza T; Popiela TJ; Heinze S; Dyczek S; Rudnicki W
    Ginekol Pol; 2021; 92(2):92-97. PubMed ID: 33448005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size.
    Fallenberg EM; Dromain C; Diekmann F; Engelken F; Krohn M; Singh JM; Ingold-Heppner B; Winzer KJ; Bick U; Renz DM
    Eur Radiol; 2014 Jan; 24(1):256-64. PubMed ID: 24048724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.